Depression and cardiovascular comorbidity by Glassman, Alexander H.
hen psychiatrists use the term “comorbidity”in
connection with depression,they are almost always refer-
ring to other psychiatric conditions,primarily anxiety or
addictive disorders,and these do co-occur with depres-
sion more often than would be expected by chance.
1
However,vascular disease,particularly the association
between depression and heart disease,is among the best-
documented of all comorbidities.
2 Not only writers and
poets,but our language itself refers to,“dying of a broken
heart.” Almost all languages, in one way or another,
express a very similar idea.However,in spite of this wide-
spread popular acceptance,scientific evidence has been
slow in emerging, and has turned out to be of a more
complicated nature than expected.
Cardiovascular disease in depressed patients
Early epidemiological studies relating melancholia to heart
disease found much higher rates of cardiovascular deaths
in melancholic patients,but their use of hospitalized pop-
ulations confounded the effects of depression and chronic
institutionalization.
3After the Second World War,more
psychoanalytic formulations,primarily “type A personal-
ity,”held sway.The time-urgent,angry,type A individual
did seem significantly more vulnerable to heart disease,
9
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Depression has long had a popular link to cardiovascular
disease and death. However, only during the last 15 years
has scientific evidence supporting this common wisdom
been available. Beginning in the early 1990s, there began
to accumulate community-based epidemiological evidence
that medically healthy, depressed patients followed for
long periods of time were at increased risk of both car-
diovascular disease and cardiac death. In the mid-1990s,
evidence appeared to indicate that depression following
a heart attack increased the risk of death. It is now appar-
ent that depression aggravates the course of multiple car-
diovascular conditions. There are two major unanswered
questions. One is whether treating depression will reduce
the risk of cardiovascular disease and death. Here, prelim-
inary, but not definitive, evidence suggests that the sero-
tonin reuptake inhibitors may be useful. The other unan-
swered question regards the mechanisms that underlie this
link between depression and cardiovascular disease. There
is strong evidence linking platelet activation, autonomic
activity, and inflammatory markers to both depression and
heart disease, but why these links exist is far less clear.     
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(e-mail: ahg1@columbia.edu)but by the mid-1970s the association became increasingly
difficult to replicate.Although we will never know for cer-
tain,in retrospect it seems likely that the adverse conse-
quences of the type A personality were real, but were
mediated by the sympathetic nervous system.
4As cardiol-
ogists began to routinely use β-blockers after myocardial
infarct (MI),the significance of the type A personality dis-
sipated.In the mid-1970s,interest returned to the concept
of major depression and cardiac disease or cardiac death.
A Danish epidemiologist was the first to show that
patients coming to treatment with a diagnosis of major
depressive disorder (MDD) or manic-depressive disease
were more likely to die from cardiac causes than the rest
of the Danish population.
5 Dozens of replications have
been reported,but it quickly became clear that these clin-
ical populations confounded diagnosis and treatment.
Using community,rather than clinical,samples circum-
vented the problem of treatment effect,because in com-
munity samples few cases were in treatment.The concern
was that community cases as opposed to clinical cases of
MDD would be considerably milder in severity,thereby
masking the relationship.However,when the first com-
munity surveys appeared in the late 1980s the relation-
ship between major depression and cardiac death per-
sisted.
6 At the same time that these first community
surveys began to appear, other studies were drawing
attention to the relationship between MDD and ciga-
rette-smoking.
7,8 Depressed patients were more likely to
smoke and less likely to be able to stop, and yet up to
that time epidemiologists had never controlled for smok-
ing while examining the relationship between depression
and heart disease.
9 It could merely be that depressed
patients were more likely to smoke, and that smoking
caused heart disease.Anda,a cardiovascular epidemiol-
ogist with the Communicable Disease Center in the US
Public Health Service,was the first to control for smok-
ing, as well as multiple other cardiac risk factors that
might influence the relationship with depression.
10 Using
a hopelessness scale rather than a diagnosis of MDD,the
relationship again persisted. The more depressed the
individual,the more likely that individual was to suffer a
MI and to die from cardiac causes.In 2002,less than 10
years after Anda’s original study,Wulsin at the National
Heart,Lung,and Blood Institute published a meta-analy-
sis that found ten large studies that now controlled for
cardiovascular risk factors,including smoking.
2All ten
found coronary heart disease to be more common in
depressed patients,and the increase was statistically sig-
nificant in seven of the ten studies.The risk existed not
only in major depression,but also in minor depression,
and it existed in both males and females (Figure 1).
The evidence that has been presented up until now is pri-
marily from epidemiological studies that started with
essentially medically healthy,depressed young adults and
followed them for long periods of time.Beginning with
medically healthy individuals avoided the potential crit-
icism that the association of depression with heart dis-
ease was merely the result of the patient’s depressive
reaction to the symptoms of heart disease.However,such
studies required either very large samples or decades of
follow-up. In the late 1980s, Carney suggested that
depression might have an adverse impact on the course
of coronary artery disease in depressed patients who
already have heart disease.
11 Using this approach,Nancy
Frasure-Smith and Françoise Lesperance were able to
show that post-MI patients with a diagnosis of MDD
were more than three and a half times more likely to die
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Selected abbreviations and acronyms
ENRICHD Enhancing Recovery in Coronary Heart
Disease
MDD major depressive disorder
MI myocardial infarct
SADHART Sertraline Antidepressant Heart Attack
Randomized Trial
SSRI selective serotonin reuptake inhibitor
Figure 1. Relative risk of coronary artery disease (CAD) in depressed
patients; a meta-analysis of 10 studies.
Adapted from ref 2: Wulsin LR, Singal BM. Do depressive symptoms
increase the risk for the onset of coronary disease? A systematic quanti-
tative review. Psychosom Med. 2003;65:201-210. Copyright © Lippincott,
Williams & Wilkins 2003.
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12 In their 1993
study,they performed a structured psychiatric examina-
tion in 222 consecutive post-MI cases at the Montreal
Heart Hospital and followed them for 6 months.Using
similar approaches, multiple investigators have now
looked at this effect of depression on the course of coro-
nary artery disease following an MI.In 2005,Evidence
Reports/Technology Assessment of the Agency for
Health Care Research and Quality (AHRQ),a branch
of the US department of Health and Human Services,
found 17 post-MI studies that assessed the relationship
between depression and subsequent mortality.
13 These
studies ranged from 4 months to as long as 10 years after
a coronary event,and concluded that the evidence was
strikingly consistent,and that post-MI depression is asso-
ciated with about a threefold increase in cardiac mortal-
ity.
2The review included studies that looked at the influ-
ence of both major and less than major depression.
Several studies performed on large post-MI samples have
now looked at the effect of increasing severity of depres-
sive symptoms,and there is a consistent positive associa-
tion between the severity of depressive symptoms and an
increased risk of mortality.
14,15 Even since the 2005
Evidence Reports/Technology Assessment
13 review was
published 2 years ago,additional evidence has continued
to accumulate.
16,17 In addition to the increased risk of
acute coronary syndromes,depression has also been asso-
ciated with increased mortality in congestive heart fail-
ure
18 and following ischemic stroke (Figure 2).
19,20
Reducing mortality from cardiovascular 
disease by treating depression
The obvious question raised by the strong association
between depression and cardiac mortality is whether
treatment of depression would reduce mortality.
Enhancing Recovery in Coronary Heart Disease
(ENRICHD)
21 was a randomized,controlled trial spon-
sored by the National Heart,Lung,and Blood Institute
(NHLBI).This trial tested whether cognitive behavioral
therapy (CBT) reduced mortality in patients after MI
compared with usual care.CBT reduced depression mod-
estly but did not alter mortality.The original ENRICHD
article
21 reported briefly that 20% of the 1853 depressed
patients received antidepressant drugs, and that those
individuals had a statistically significant (42%) reduction
in a combined end point of death or recurrent MI, but
this observation came from data that was neither ran-
domized nor controlled.Several years later,Taylor pub-
lished a much more detailed analysis of antidepressant
drug use in the ENRICHD trial.
22 Among many other
problems,the absence of randomization was not subtle;
only those known to be at higher risk for cardiac events
were offered antidepressants.In addition,there was no
control over when the drug was started or stopped.
Nevertheless,the sample was very large,the number of
events reasonable,and the magnitude of the effect is hard
to ignore (hazard ratio,0.57 [95% confidence interval,
0.38-0.84]).This is a post-hoc observation,not an a priori
test of a hypothesis. However, it is a strong signal that
antidepressant drugs can reduce life-threatening events.
Another hint that antidepressants can reduce post-MI
mortality came from the Sertraline Antidepressant Heart
Attack Randomized Trial (SADHART).Patients admit-
ted with either acute MI or unstable angina were screened
for MDD and, if suitable, randomized to sertraline or a
placebo to test the drug's safety and efficacy.
23 This was
done as a stepping-stone towards testing whether a selec-
tive serotonin reuptake inhibitor (SSRI) could reduce
mortality.SADHART did demonstrate the safety and effi-
cacy of sertraline.It also,rather unexpectedly,showed a
reduced risk of death and recurrent MI similar to that seen
in the ENRICHD trial.However,with only 369 patients,
SADHART had almost 10-fold fewer patients than a
power analysis suggested would be needed to adequately
evaluate the effect of sertraline on mortality.Although the
study was randomized and controlled,the results,as would
be expected,did not reach statistical significance.
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Figure 2. Cumulative mortality in depressed and nondepressed patients
following myocardial infarct (MI).
Adapted from ref 12: Frasure-Smith N, Lesperance F, Talajic M. Depression
following myocardial infarction. Impact on 6-month survival. JAMA. 1993
20;270:1819-1825. Copyright © American Medical Association 1993
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30A 2003 Danish poststroke study also showed a strong
trend for reduction of life-threatening events by SSRIs.
24
Although SSRI treatment was randomized and con-
trolled,observations of reduced morbidity and mortality
were made post hoc and were not evaluated blindly.
None of these studies constitutes an adequate scientific
test of the question.SADHART and ENRICHD both
examined depressed, postcoronary patients and found
evidence that SSRIs might reduce medical morbidity.
Interestingly, the stroke trial was not conducted in
depressed patients,but rather was a depression preven-
tion trial.The three trials taken together offer strong evi-
dence that SSRIs may reduce post-MI medical morbid-
ity and mortality,but a definitive clinical trial is needed.
The Danish stroke study is interesting,because the SSRI
was given exclusively to nondepressed patients. This
raises the issue of whether the benefit of SSRIs in
patients with vascular disease may extend beyond
depressed patients.There is a single, recent poststroke
study with a similar design that failed to find either a sig-
nificant ability of an SSRI to prevent depression or to
reduce subsequent medical events.
25
The suggestion that SSRIs may have a beneficial effect
on cardiovascular outcomes comes not only from ran-
domized trial data,but from epidemiological studies as
well. Initially, Cohen examined the hospital and phar-
macy records of 55 000 New York City health and hospi-
tal workers, and found those taking a tricyclic antide-
pressants (TCA) were twice as likely to be hospitalized
with a diagnosis of MI than those not prescribed an anti-
depressant drug.
26 In contrast,individuals prescribed an
SSRI were no more likely to have an MI.This observa-
tion of a beneficial effect of SSRIs has been replicated in
four of the five epidemiological studies that are available
to address this issue.
27-31 However,unlike SADHART and
ENRICHD,these are epidemiological studies,not clini-
cal trials.Although suggestive,epidemiological data can
not establish a cause-and-effect relationship.These stud-
ies primarily examine the rate of new MI in individuals
who are assumed to be depressed because they are tak-
ing antidepressants,compared with the rate in individu-
als who are free of antidepressants and assumed not to
be depressed. If SSRIs do reduce the risk of MI as the
data suggests,this raises an interesting issue.SSRIs but
not TCAs are known to reduce the “stickiness” of
platelets. This effect, although involving mechanisms
somewhat distinct from those of aspirin,could result in n
reduction in the risk of MI similar to that provided by
aspirin.
32,33This does not,however,imply that the same
mechanism involved in the prevention of MI in patients
with no prior history of cardiac disease would be respon-
sible for the reduction in mortality in patients given an
SSRI following an MI, as suggested by the data from
SADHART and ENRICHD. These post-MI patients,
unlike the depressed patients with no known prior his-
tory of cardiac disease,will already be receiving multiple
antiplatelet drugs,and it is unlikely that the addition of
another antiplatelet compound would have a dramatic
impact on mortality.
Another interesting observation from Cohen’s study in
hospital workers is related to the risk of developing heart
disease among patients suffering depression.
26 He
observed that the 1653 workers who filled prescriptions
for TCAs (and were presumably depressed) were more
than 100% more likely to have an MI than those 55 000
individuals who were not taking TCAs.This compares
with the Wulsin ten-study meta-analysis
2 where
depressed individuals had essentially a 65% increase in
the risk of developing coronary disease.Although the
studies are not absolutely comparable,the major differ-
ence is that all of the studies in the Wulsin analysis con-
trolled for smoking as well as other cardiac risk factors,
while Cohen had no data on,and could not control for,
such risk factors.Both studies were based on large sam-
ples and,although this is not an ideal way to approach
the issue,they illustrate two different points of view.The
epidemiologist asks whether depression makes an inde-
pendent contribution to the risk of heart disease,or if it
is only an apparent increase accounted for by the fact
that depressed patients are more likely to smoke, and
smoking causes heart disease. Wulsin’s data says that
there is a 65% increase beyond that accounted for by any
known risk factors.The clinician faced with a depressed
patient may ask how much more likely this person is to
develop coronary artery disease than a similar person
without depression.For the specific patient,there exists
both the independent risk associated with depression
plus those cardiac risk factors known to be associated
with depression such as smoking,poor health behaviors,
obesity,diabetes,reduced physical activity,etc.Thus,while
Wulsin’s estimate of a 65% increase in risk may be sci-
entifically more accurate,Cohen’s estimate of more than
a 100% increase is likely to be a clinically more relevant
assessment of the problem.
Up to this point,what has been discussed is the evidence
that medically healthy,depressed patients are more likely
State of the art
12Depression and cardiovascular comorbidity - Glassman Dialogues in Clinical Neuroscience - Vol 9 . No.1 . 2007
13
to develop and die of heart disease than those without
depression,and that depressed patients who already have
heart disease, particularly acute coronary syndromes
(ACS—this refers to both MI and unstable angina) are
at a markedly increased risk of cardiac death.In addition,
evidence has been reviewed suggesting that SSRI treat-
ment may possibly reduce this medical morbidity and
mortality. What has not been discussed is what drives
these associations.It is important to make a number of
distinctions.There are undoubtedly multiple pathways
connecting depression and heart disease,and although
some pathways may operate in both medically healthy
depressed patients and in those with pre-existing cardiac
disease, some could be unique to one situation or the
other. In addition, the mechanisms that lie behind the
reduction in risk with SSRIs (if that reduction is con-
firmed),may also not be exactly the same as the mech-
anism that created the risk.
Multiple mechanisms linking depression and heart dis-
ease have been suggested.Depression has regularly been
demonstrated to lower adherence to prescribed medica-
tion and secondary prevention measures
34,35 among car-
diac patients. Studies of noradrenergic activity,
36 auto-
nomic activity,
37,38 heart rate variability (HRV),
39,40 and
platelet biomarkers,
41-43 as well as inflammatory mark-
ers,
43-46 have regularly found differences in clinically
depressed compared with nondepressed post-MI patients
that favor the development of heart disease. Levels of
omega-3 fatty acids are known to vary between
depressed and nondepressed populations and influence
the risk of ischemic heart disease.
47The possibility also
exists that depression and vascular disease share certain
vulnerability genes.
48 However,why depression and heart
disease are so closely associated is far from clear. A
detailed discussion of each of these potential mechanisms
is beyond the scope of this review,but recent references
are supplied.
49,50
Although not as immediately obvious as the question of
potential mechanisms,a very important issue is that of
when these mechanisms come into play.The relationship
between depression and heart disease that has been doc-
umented is an association.Associations do not explain
causality,and can result from multiple different pathways.
Certainly some of the depressive symptomatology and
even some of the major depression that arises for the first
time following a coronary event is a reaction to that med-
ical event.However,there is considerable evidence that
such cases are not an explanation for most of the associ-
ation between depression and heart disease.Two differ-
ent pieces of information are pertinent. Earlier in this
review it was mentioned that the 1993 study by Anda was
the first epidemiological study to control for cardiac risk
factors.It was also the first study to carefully control for
prior medical illness.
10 It was based on a follow-up of the
National Health and Human Nutrition Examination
Survey (NHANES) and involved over 3000 individuals
collected at that time for more than 13 years.At baseline,
individuals in this study had both a physical exam and
laboratory tests,and anyone with known medical illness
was excluded.In addition,to be certain that any depres-
sion found at baseline was not the result of subtle symp-
tomatology that distressed the individual but was not rec-
ognized or reported, the first 21/2 years of data were
excluded from the analysis.As a result,the cardiac dis-
ease and deaths that occurred over the last 11 years could
unequivocally be attributed to pre-existing depression.
When Wulsin published his meta-analysis 10 years later,
all 10 studies that were included controlled in one way or
another for baseline medical illness.
The other evidence indicating that pre-existing heart dis-
ease is not the major cause of the association between
depression and heart disease comes from the SAD-
HART study.When we initially planned that study,our
expectation was that many of the cases of major depres-
sion that are observed in the intensive care or step-down
units after hospitalization for MI would be mild and of
very short duration.That was our expectation,because
we felt that an MI causes both severe psychological and
physiological stress,and it would not be surprising that in
vulnerable people, it could produce depression.
51 Our
expectation that many cases of post-MI depression would
be mild was confirmed,but the idea that they would for
the most part begin in the hospital after the coronary
event and be of short duration was not correct. Fifty-
three percent of the cases began before hospitalization.
Coronary events,either MI or unstable angina,are acute
events.Ninety percent of patients hospitalized for MI are
hospitalized within the first 24 hours.Ninety-three per-
cent of the depressions that began before hospitalization
began more than a month before hospitalization, and
that is probably an underestimate of how many depres-
sions actually began before the coronary event. SAD-
HART was a clinical trial that randomized patients to
sertraline or placebo, not an epidemiological study. It
would not be considered ethical to recruit post-MI
patients who were already being treated with antide-pressant drugs into the trial. This would mean taking
someone who was on antidepressant medication,stop-
ping their medication,and randomizing them potentially
to a placebo.About 20% of patients who met the crite-
ria for major depression were already receiving an anti-
depressant drug.As a result,probably closer to 70% of
the patients observed to be depressed following their MI
in the SADHART study actually had that depression
prior to the coronary event. For these patients, the
depression may have contributed to the coronary event,
but the coronary event did not precipitate the depression.
There was a similar incidence of MDD cases beginning
before hospitalization in the ENRICHD trial (Carney,
personal communication).
Is cardiovascular disease 
a cause of depression?
The fact that most coronary disease follows rather than
precedes depression does not imply that depression
causes coronary artery disease.It could be that some of
the biological changes associated with depression do
increase the risk of coronary or vascular disease.
However, it is also perfectly plausible that preceding
genetic or environmental events could lead to biological
changes conducive to both conditions.When thinking
about the relationship between depression and heart dis-
ease,it is easy to make the mistake of looking for a sin-
gle cause.
For a period of time, it was popular to consider the
platelet abnormalities associated with depression as the
cause of the association between depression and heart
disease.However,it is extremely unlikely that there will
turn out to be any single cause.Platelets,health behav-
iors,inflammatory markers,autonomic abnormalities,etc,
will each undoubtedly turn out to play a role.Not only
will there be multiple mechanisms;in any given patient
the degree to which a given mechanism creates the asso-
ciation will vary.In addition,the mechanisms underlying
the association between depression and heart disease
may not be exactly the same as the mechanisms under-
lying the ability of SSRI drugs to alter that association.
Once an individual develops depression,especially if it is
recurrent,that illness brings with it a number of health
behaviors that will unquestionably increase the risk for
vascular disease. It has repeatedly been shown that
depressed individuals are less likely to take care of their
health,they are less likely to exercise,and are more likely
to be obese and find it difficult to stop smoking.In addi-
tion to issues directly connected to being depressed,there
are some issues that precede depression; this may
increase the risk for both depression and ischemic heart
disease. A number of epidemiological studies have
looked at early adverse experiences and their impact on
multiple subsequent behaviors.
52,53There is a strong asso-
ciation between early abuse and neglect and subsequent
depression,drug abuse,and ischemic heart disease.There
is some evidence to suggest that childhood maltreatment,
including both abuse and neglect,influences depression
and heart disease in ways that are gender-dependent.
54
Evidence from the National Comorbidity Study indicates
that although males are usually at higher risk for
ischemic heart disease and females at higher risk for
depression,early childhood maltreatment increases the
risk of depression in males, while in females maltreat-
ment raises the risk of ischemic heart disease in women
so that it resembles that usually seen only in men.
In addition to childhood adverse events influencing both
the risk for heart disease and depression,another mech-
anism by which both heart disease and depression could
have common roots without either condition directly
causing the other is shared genes.Data from the Vietnam
Era Twin Registry in 2731 twin pairs showed a shared
genetic risk between depression,hypertension,and heart
disease.
55 Recently,there has been considerable evidence
that functional variants in the serotonin transporter can
alter the relationship between stress and subsequent
depressive episodes.Individuals with two short alleles at
the serotonin transporter locus were more sensitive to
stressful events than individuals with either one or two
long alleles.
56Whether these same functional variants in
a serotonin transporter can influence the risk of ischemic
heart disease is at present unknown.
Discussion
There is strong evidence that depression is associated with
an increased risk of cardiovascular disease and cardiac
death.In studies of large populations free of medical dis-
ease,after controlling for all known cardiovascular risk fac-
tors,it is those individuals with baseline depression that
are more likely to develop cardiovascular disease.And,
once they develop coronary artery disease,those who are
observed to be depressed are at markedly increased risk
of cardiac morbidity and mortality. Interestingly, this
increased risk is not limited to patients with major depres-
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sion.Patients with less than major depression,who have
even modest increases in symptoms of depression,show a
higher risk of recurrent infarction and cardiac death.
14,15
The more severe the depression, the higher the risk.
Depression also increases the risk of death and medical
complications after coronary bypass surgery
57 and in
patients with heart failure as well.
18 Similar to the risk of
cardiovascular disease,individuals with depression are also
at higher risk of ischemic stroke, and after a stroke,
patients who are depressed are at higher risk of medical
complications and death.
19,20,58There is even evidence that
antidepressant treatment reduces these medical risks.
59
Most cases of major depression have their onset in the
early adult years, and many become recurrent. This
review has focused on these early-onset cases because
they are the most common,and because examining such
cases avoids confusing whether depression precedes vas-
cular disease or whether the early symptoms of vascu-
lar disease are responsible for the onset of depression.
There is no question that depression can precede vascu-
lar disease by decades.To what degree this early-onset
depression itself leads to vascular disease,and to what
extent the association is the result of a common
antecedent,remains to be clarified.In addition to depres-
sion earlier in life,some cases of major depression clearly
have their initial onset later in life, and a number of
investigators have suggested that at least some of these
cases are secondary to vascular changes in the brain.The
earliest suggestions of such a relationship came from
poststroke studies
60 and more recently from imaging
studies. Imaging studies have indicated that late-onset
depression is more likely to show evidence of so-called
white matter hyperintensities which are associated with
hypertension and often thought to be evidence for arte-
rial sclerotic changes in the brain.
61,62 These issues are
complex and are not dealt with in this review.
Nevertheless, it is worthwhile to realize that the rela-
tionship between depression and heart disease can be a
two-way street.Most depressions seen after MI do have
their onset long before the coronary episode.However,
a significant number of individuals will develop their first
depression after a coronary event.A high percentage of
such depressions recover spontaneously, but a third of
such individuals respond poorly to usual treatments,even
though it is their first depression and is often mild.It is
intriguing to consider whether depression in these cases
has a vascular or aging component.
There remain two major unsettled questions.The first is
whether treating depression reduces the risk of vascular
disease.Although there is some suggestion that this is the
case,the evidence available is not adequate,and a defin-
itive trial is required.The second is why there is such a
strong association between depression and vascular dis-
ease.Here,the available evidence is even more limited.
Depression and cardiovascular disease are the two
largest public health problems in the Western world,and
their appropriate prevention and treatment is an enor-
mous public health issue. ❏
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Depresión y comorbilidad cardiovascular
Popularmente la depresión se ha relacionado hace
largo tiempo con la enfermedad cardiovascular y la
muerte. Sin embargo, sólo durante los últimos quince
años se ha contado con evidencia científica que res-
palde este conocimiento popular. Al inicio de la
década de los noventa se comenzó a acumular evi-
dencia epidemiológica de estudios en la comunidad
de pacientes depresivos, médicamente sanos, que fue-
ron seguidos por largos períodos de tiempo en quie-
nes se encontró un mayor riesgo tanto de enfermedad
cardiovascular como de muertes por causa cardíaca. A
mediados de los noventa, la evidencia pareció indicar
que la depresión post ataque cardíaco aumentaba el
riesgo de muerte. Hoy está claro que la depresión
agrava el curso de diversas patologías cardiovascula-
res. Hay dos preguntas principales sin responder. Una
es si acaso el tratar la depresión reducirá el riesgo de
enfermedad cardiovascular y de muerte. Para esta pre-
gunta la evidencia sugiere, preliminar pero no defi-
nitivamente, que los inhibidores de la recaptación de
serotonina pueden ser útiles. La otra pregunta sin res-
ponder se refiere a los mecanismos que subyacen a la
relación entre depresión y enfermedad vascular. Existe
una poderosa evidencia que relaciona la activación
plaquetaria, la actividad autonómica y los marcadores
de la inflamación tanto con la depresión como con la
enfermedad cardíaca, pero el porqué existen estas
relaciones aun no se ha aclarado.   
Dépression et comorbidité cardiovasculaire
L’idée qu’il existe un lien entre dépression, maladie
cardiovasculaire et décès est ancienne et populaire. Il
a fallu néanmoins attendre ces 15 dernières années
pour disposer d’arguments scientifiques confirmant
ce bon sens commun. Au début des années 90, des
preuves épidémiologiques basées sur la population
générale ont commencé à s’accumuler en faveur de
l’augmentation du risque conjoint de maladie car-
diovasculaire et de décès cardiaque chez des patients
déprimés, médicalement sains et suivis sur de longues
périodes. Au milieu des années 90, il a été montré
que la dépression après une crise cardiaque aug-
mentait le risque de décès. Nous savons maintenant
que la dépression aggrave l’évolution de nombreuses
maladies cardiovasculaires. Deux questions majeures
restent sans réponse : traiter la dépression réduira-t-
il le risque de maladie cardiovasculaire et de décès ?
Les inhibiteurs de la recapture de la sérotonine sem-
blent répondre positivement au premier abord, mais
pas de façon définitive. L’autre question concerne les
mécanismes qui sous-tendent ce lien entre dépression
et maladie cardiovasculaire. Activation plaquettaire,
activité autonome et marqueurs inflammatoires sont
très certainement liés à la dépression et à la maladie
cardiovasculaire mais pourquoi le sont-ils ? Voilà qui
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